Indian subsidiary of Merck Sharp and Dohme (MSD), a drug firm has decided to enter into voluntary licensing agreements for investigational oral antiviral drug candidate ‘molnupiravir’, it said on Tuesday.
The drug is being studied for the treatment of Covid-19 with Indian firms Sun Pharma, Cipla, Dr Reddy’s, Emcure Pharma and Hetero Labs.
Molnupiravir is currently being studied in a Phase 3 trial for treatment of non-hospitalized patients with confirmed Covid-19, MSD India said in a statement.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…